Foundation for Physical Medicine & Rehabilitation and Mallinckrodt Pharmaceuticals Announce New Grant Partnership

Mar 31, 2014, 09:00 ET from Foundation for Physical Medicine and Rehabilitation

ROSEMONT, Ill., March 31, 2014 /PRNewswire-USNewswire/ -- The Foundation for Physical Medicine & Rehabilitation (FPM&R) and Mallinckrodt Pharmaceuticals are partnering in the development of a new research grant.  The Mallinckrodt Acute Pain Management Research Grant will offer up to three grants of $10,000 each in 2014 for research on the use of acute opioids by physiatrists in physical medicine and rehabilitation, with special consideration given to outcomes research. Applications are being accepted through May 01, 2014.  The FPM&R Awards and Grants Review Committee will independently score all proposals and recommend a winner to the FPM&R Board of Directors.  The award will be presented at the 2014 Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, November 2014.

Phyllis Anderson, MA, Executive Director of the FPM&R stated: "Every year, the Foundation receives up to six times as many qualified research grant applications than we are able to fund.  We established a Pain Management and Spine Care Fund in 2013 to address a great need for evidence and outcomes research in this area.  Many thanks to Mallinckrodt for joining us in support of this research grant we are offering specifically for acute pain management."

"This research grant underscores our commitment to developing and providing new treatment options for the millions of patients who suffer from pain," said Dr. Mario Saltarelli, Senior Vice President and Chief Science Officer, Mallinckrodt. "As experts in the development of complex products to help manage pain, Mallinckrodt is proud to partner with the FPM&R in this important long-term effort."

About The Foundation for Physical Medicine and Rehabilitation:

The Foundation for Physical Medicine and Rehabilitation, a 501(c)(3) nonprofit organization, strives to restore health, improve function, minimize pain and enhance quality of life for individuals with disability through research and education in the field of physical medicine and rehabilitation.  For more information, visit

About Mallinckrodt

Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and commercial presence in roughly 70 countries. The company's fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit

Contact: Jennifer L. Vince
Ph: 312-593-4470

SOURCE Foundation for Physical Medicine and Rehabilitation